JointHealth™ express August 21, 2020
Reminder: Call for patient input on filgotinib for moderate to severe rheumatoid arthritis
Do you live with moderate to severe rheumatoid arthritis? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for filgotinib for moderate to severe rheumatoid arthritis.
The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).
To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.
These are the questions they are asking:
Please contact us at feedback@jointhealth.org to provide your input or arrange for a phone interview at 604-974-1366.
Reminder: Call for patient input on filgotinib for moderate to severe rheumatoid arthritis
Do you live with moderate to severe rheumatoid arthritis? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for filgotinib for moderate to severe rheumatoid arthritis.
The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).
To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.
These are the questions they are asking:
- Disease experience: How does rheumatoid arthritis impact patients’ and caregivers’ day-to-day life and quality of life? Are there any aspects of rheumatoid arthritis that are more important to control than others?
- Experiences with currently available treatments: How well are patients and caregivers managing their rheumatoid arthritis with currently available treatments? Examples of the types of information to be included in the answer are:
- What therapy are patients currently using for rheumatoid arthritis?
- How effective are current therapies in controlling common aspects of rheumatoid arthritis? What benefits have patients’ experienced?
- What side effects have been experienced? Are there adverse effects that are more difficult to tolerate than others?
- Are there any difficulties accessing current therapy (cost, travel to clinic, time off work)?
- Are there any difficulties receiving the treatment (swallowing pills, infusion lines)?
- How do current treatments impact caregivers' daily routine or lifestyle?
- Improved outcomes: What improvements would patients and caregivers like to see in a new treatment such as filgotinib that is not achieved in currently available treatments?
- How might daily life and quality of life for patients, caregivers, and families be different if filgotinib provided those desired improvements?
- What trade-offs do patients, families, and caregivers consider when choosing therapy? For example, would patients be willing to experience serious adverse effects with filgotinib if they experienced other benefits from the medication?
- Experiences with filgotinib: What experiences have patients had to date with filgotinib as part of a clinical trial or through a manufacturer's compassionate supply?
- Compared to any previous therapies’ patients have used, what benefits have been experienced with filgotinib?
- What disadvantages have been experienced?
- How have the benefits and disadvantages of filgotinib impacted the lives of patients, caregivers, and families?
- Is filgotinib easier to use than previous therapies? If so, how?
- Has filgotinib caused adverse effects? Which adverse effects are acceptable (i.e. can be tolerated) and which ones are not?
Please contact us at feedback@jointhealth.org to provide your input or arrange for a phone interview at 604-974-1366.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.